Survey Finds Patients’ Insurance Status, Out-Of-Pocket Expenses Figure Prominently In Oncologists’ Use Of Genomic Testing

MedPage Today (1/16, Bankhead) reports, “Patients’ insurance status and out-of-pocket (OOP) expenses figured prominently in oncologists’ use of genomic testing to guide treatment decisions, according to a national survey.” Roughly “half of the 1,049 oncologists surveyed said insurance and OOP expenses were ‘very important’ considerations, and another 30% said the factors were ‘somewhat important.’” The findings were published in JCO Oncology Practice.